Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Exclusion criteria

• ✕. Patients must provide informed written consent
• ✕. ECOG performance status 0-2.
• ✕. Clinical stage operable I, II or III invasive mammary carcinoma, which is ER-positive by IHC and HER2-negative by Herceptest (0 or 1+) or not amplified by in situ hybridization as per routine clinical testing.
• ✕. Measurable tumor. Measurable disease: a mass that can be reproducibly measured by physical exam, mammogram or ultrasound and is at least 1 cm in size
• ✕. Post-menopausal female subjects ≥18 years of age, as defined by any of the following:
• ✕. No prior chemotherapy for this primary breast cancer.
• ✕. Patients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer.
• ✕. Women may have been taking tamoxifen or raloxifene as a preventive agent prior to study entry but must have discontinued the drug for at least 14 days prior to study enrollment.